Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 9, 2008, Pages 443-452

  Tiessen, Renger G ^a   Castaigne, J P ^b   Dreyfus, J F ^b   Nemansky, M ^a   Kruizinga, H H ^a   van Vliet, A A ^a  

^a PRA Health Sciences   (Netherlands)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Conjugation; Glucagon like peptide 1; Pharmacokinetics

Indexed keywords

CJC 1131; GLUCOSE; METOCLOPRAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERVENTILATION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 52149102047     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46443     Document Type: Article

References (10)

1. Bridon DP et al. ADA. 2002; abstr. ref. 164.
2. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995; 80: 952-957.
3. Drucker DJ. Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care. 2003; 26: 2929-2940.
4. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ. Development and characterization of a glucagon-like peptide 1-albumin conjugate. Diabetes. 2003; 52: 751-759.
5. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3082-3089.
6. Lawrence B, Wen SY, Jette L, Castaigne JP. CJC-1131, the novel long acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing. Diabetes. 2002; 51: 2 A340-OR.
7. Leger R, Thibaudeau K, Robitaille M, Quraishi O, van Wyk P, Bousquet-Gagnon N, Carette J, Castaigne JP, Bridon DP. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett. 2004; 14: 4395-4398.
8. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006; 29: 435-449.
9. Wen S, Wilson S, Trebec D, Pham K, Castaigne J, Lawrence B. CJC-1131, a long-acting GLP-1 analogue, exhibits safety and tolerability in dogs. Toxicol Sci. 2003; 72: S1-S48.
10. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.